Primo Biotechnology

Future in Precision

Primo

About Primo

Primo Biotechnology embodies disruptive innovation that advances clinical procedures for cancer management with molecular image-guided and targeted diagnosis and therapy. We are determined to lead in precision radiopharmaceutical approaches for the diagnosis and treatment of cancer.

About Us

News

April 24, 2025

Primo’s Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine.

March 19, 2025

Primo Partners with ABX to Bring PB01 Closer to Taiwan’s Prostate Cancer Market

January 13, 2025

Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific

January 9, 2025

Primo Biotechnology Partners with Antelope Surgical Solutions for World’s First FDA-Approved Phase I/II Trial of AS1986NS

Why Primo Exceeds

The Primo team comprises professionals who own several patents in novel radiopharmaceuticals and new manufacturing processes, and are experienced in applications of TFDA/CDE in clinical investigations using new drugs. We are also highly specialized in radiopharmaceutical development.

Isotopes

Lu-177 Ilumira

Novel radioligand theranostics

Advanced radiopharmaceuticals are designed and used as precision theranostics for cancers.

Pre-clinical studies

Primo provides pre-clinical research services, including specific animal models and in-vivo animal imaging.We are devoted supporters of the development of small-molecule drugs and therapeutic antibodies.

CRO/CDMO of Radiopharmaceutic

We offer one-stop and customized services that include scientific consulting, technical support, and regulatory applications for various clinical trials using common or novel radiopharmaceuticals.

Research

Clinical Impact of Radium-223 on Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

This study poster was presented at 2024 Annual Conference of Society of Nuclear Medicine, Taiwan.

An updated radiosynthesis of [18F]PSMA-1007 by a Neptis RS synthesizer with fully EP compliant quality control test at the medical center in Northern Taiwan.

This study poster was presented at 2024 Annual Conference of Society of Nuclear Medicine, Taiwan.

The radiosynthesis of [18F]fluoroacetate by a Tracerlab MX synthesizer in Shin-Kong Memorial Hospital.

This study poster was presented at 2024 Annual Conference of Society of Nuclear Medicine, Taiwan. Read More